Volume 21 Issue 3
Mar.  2023
Turn off MathJax
Article Contents
Article Navigation >  Chinese Journal of General Practice  > 2023  >  21(3): 458-462
SUN Lihong, KONG Fangfang, ZHAO Qi, PAN Jianfeng, PEI Jingbo. Effectiveness and compliance analysis of vonoprazan fumarate combined with targeted health education intervention on patients with chronic atrophic gastritis with positive Helicobacter pylori[J]. Chinese Journal of General Practice, 2023, 21(3): 458-462. doi: 10.16766/j.cnki.issn.1674-4152.002907
Citation: SUN Lihong, KONG Fangfang, ZHAO Qi, PAN Jianfeng, PEI Jingbo. Effectiveness and compliance analysis of vonoprazan fumarate combined with targeted health education intervention on patients with chronic atrophic gastritis with positive Helicobacter pylori[J]. Chinese Journal of General Practice, 2023, 21(3): 458-462. doi: 10.16766/j.cnki.issn.1674-4152.002907
shu

Effectiveness and compliance analysis of vonoprazan fumarate combined with targeted health education intervention on patients with chronic atrophic gastritis with positive Helicobacter pylori

doi: 10.16766/j.cnki.issn.1674-4152.002907

  • Department of Gastroenterology, Jiangnan Hospital Affiliated to Zhejiang University of Traditional Chinese Medicine, Hangzhou, Zhejiang 311201, China

Funds:

 2021ZB241

  • Received Date: 2022-10-29
    Available Online: 2023-04-19
    Abstract
  •   Objective  To explore the effects of vonoprazan fumarate combined with targeted health education intervention on Helicobacter pylori (Hp) eradication rate, gastrointestinal hormones and treatment compliance in patients with Hp positive chronic atrophic gastritis.  Methods  As a retrospective cohort study, 90 patients with Hp-positive chronic atrophic gastritis admitted to our hospital from January 2020 to September 2022 were selected and divided into observation group and control group according to treatment methods, with 45 patients in each group. Patients in both groups were treated with amoxicillin + pectin ingot + clarithromycin. Patients in the control group were treated with omeprazole to clear Hp and received routine nursing intervention. Patients in the observation group were treated with vonoprazan fumarate combined with targeted health education intervention. The clinical efficacy and Hp clearance after 8 weeks of treatment, the changes of serum motilin (MLT), gastrin 17 (GAS-17) and pepsinogen levels before and after treatment, and the influence of treatment compliance were observed in the two groups.  Results  The total effective rate of treatment in the control group was 77.78% (35/45), which was significantly lower than that in the observation group [100.00%(45/45), P < 0.05]. The Hp clearance rate in the observation group was 84.44% (38/45), which was significantly higher than that in the control group [68.89% (31/45), P < 0.05)]. After treatment, After treatment, there were statistically significant differences in MLT, GAS-17 and pepsinogen between the two groups (all P < 0.05), the above indexes in the two groups were significantly improved compared with those before treatment (all P < 0.05). The incidence of adverse reactions in the observation group was 4.44% (2/45), which was not significantly different from 8.89% (4/45) in the control group (P > 0.05). The compliance rate of the observation group was 97.78% (44/45), which was significantly higher than 75.56% (34/45) of the control group (P < 0.05).  Conclusion  Vonoprazan fumarate combined with targeted health education intervention can help to cure Hp infection in patients with Hp positive chronic atrophic gastritis, improve the expression levels of motilin, gastrin 17 and pepsin, and improve treatment compliance, with good safety.

     

    • FullText(HTML)
  • loading
    • References(28)
  • [1]
    MASSIRONI S, CAVALCOLI F, ZILLI A, et al. Relevance of vitamin D deficiency in patients with chronic autoimmune atrophic gastritis: a prospective study[J]. BMC Gastroenterol, 2018, 18(1): 172. doi: 10.1186/s12876-018-0901-0
    [2]
    TOYOSHIMA O, TANIKAWA C, YAMAMOTO R, et al. Decrease in PSCA expression caused by Helicobacter pylori infection may promote progression to severe gastritis[J]. Oncotarget, 2018, 9(3): 3936-3945. doi: 10.18632/oncotarget.23278
    [3]
    魏慧娜. 老年慢性萎缩性胃炎的临床特征及病情进展的影响因素分析[J]. 临床研究, 2022, 30(6): 25-28. https://www.cnki.com.cn/Article/CJFDTOTAL-LCYN202206008.htm

    WEI H N. Analysis of clinical features and influencing factors of disease progression in elderly patients with chronic atrophic gastritis[J]. Clinical Research, 2002, 30(6): 25-28. https://www.cnki.com.cn/Article/CJFDTOTAL-LCYN202206008.htm
    [4]
    杨敏. PGⅠ、PGⅡ、PGR及G-17检测在胃癌及萎缩性胃炎诊断中的应用效果[J]. 临床医学研究与实践, 2020, 5(3): 112-114. https://www.cnki.com.cn/Article/CJFDTOTAL-YLYS202003047.htm

    YANG M. Application effects of detection of PG Ⅰ, PG Ⅱ, PGR and G-17 in the diagnosis of gastric cancer and atrophic gastritis[J]. Clinical Research and Practice, 2020, 5(3): 112-114. https://www.cnki.com.cn/Article/CJFDTOTAL-YLYS202003047.htm
    [5]
    武国兵, 程晓龙, 于潇, 等. 幽门螺杆菌相关性慢性萎缩性胃炎与胃癌关系的研究进展[J/OL]. 协和医学杂志: 1-9. (2022-07-29)[2022-10-25]. https://kns.cnki.net/kcms/detail/11.5882.R.20220729.1021.004.html.

    WU G B, CHENG X L, YU X, et al. Research progress of the relationship between chronic atrophic gastritis associated with Helicobacter pylori and gastric cancer[J/OL]. Concord Medical Journal: 1-9. (2022-07-29)[2022-10-25]. https://kns.cnki.net/kcms/detail/11.5882.R.20220729.1021.004.html.
    [6]
    杜菲, 董银凤, 陈天辉. 幽门螺杆菌根治与复发研究进展[J]. 国际流行病学传染病学杂志, 2020, 47(2): 169-170, 173. doi: 10.3760/cma.j.cn331340-20190731-00137

    DU F, DONG Y F, CHEN T H. Advances on eradication and recurrence of Helicobacter pylori[J]. International Journal of Epidemiology and Infectious Disease, 2020, 47(2): 169-170, 173. doi: 10.3760/cma.j.cn331340-20190731-00137
    [7]
    SHAH S C, PIAZUELO M B, KUIPERS E J, et al. AGA clinical practice update on the diagnosis and management of atrophic gastritis: expert review[J]. Gastroenterology, 2021, 161(4): 1325-1332.e7. DOI: 10.1053/j.gastro.2021.06.078.
    [8]
    郑益, 王文彬, 单春燕. 富马酸伏诺拉生片联合兰索拉唑治疗胃食管反流性咽喉病的临床效果[J]. 中国医药导报, 2022, 19(24): 103-106. https://www.cnki.com.cn/Article/CJFDTOTAL-YYCY202224018.htm

    ZHENG Y, WANG W B, SHAN C Y. Clinical effect of Fumarate Vorolasan Tablets combined with Lansoprazole in the treatment of gastroesopha-geal reflux pharyngo-laryngeal disease[J]. China Medical Herald, 2022, 19(24): 103-106. https://www.cnki.com.cn/Article/CJFDTOTAL-YYCY202224018.htm
    [9]
    郑延和, 赵晓芸, 魏宗苹. 富马酸伏诺拉生治疗难治性反流性食管炎疗效观察[J]. 实用药物与临床, 2022, 25(9): 808-812. doi: 10.14053/j.cnki.ppcr.202209009

    ZHENG Y H, ZHAO X Y, WEI Z P. Therapeutic effect of vonoprazan fumarate on refractory reflux esophagitis[J]. Practical Pharmacy and Clinical Remedies, 2022, 25(9): 808-812. doi: 10.14053/j.cnki.ppcr.202209009
    [10]
    扈晓娇. 幽门螺杆菌相关胃炎经替普瑞酮替代铋剂四联疗法治疗的疗效[J]. 中国冶金工业医学杂志, 2022, 39(2): 147-148. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGYJ202202013.htm

    HU X J. Efficacy of teprenone instead of bismuth quadruple therapy in the treatment of Helicobacter pylori associated gastritis[J]. Chinese Medical Journal of Metallurgical Industry, 2022, 39(2): 147-148. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGYJ202202013.htm
    [11]
    康利. 胃复春联合替普瑞酮对慢性萎缩性胃炎患者氧化应激及炎症因子的影响[J]. 世界最新医学信息文摘, 2020, 20(84): 2.

    KANG L. Effects of Weifuchun combined with teprenone on oxidative stress and inflammatory factors in patients with chronic atrophic gastritis[J]. World Latest Medicine Information, 2020, 20(84): 2.
    [12]
    张俊杰, 李慧朋, 吴旭瑞. Hp相关性慢性萎缩性胃炎患者应用叶酸、VB12联合治疗的效果观察[J]. 黑龙江医药科学, 2022, 45(3): 45-46. https://www.cnki.com.cn/Article/CJFDTOTAL-KXJY202203028.htm

    ZHANG J J, LI H M, WU X R. To observe the effect of folic acid combined with VB12 in the treatment of patients with HP-associated chronic atrophic gastritis[J]. Heilongjiang Medicine and Pharmacy, 2022, 45(3): 45-46. https://www.cnki.com.cn/Article/CJFDTOTAL-KXJY202203028.htm
    [13]
    DRA SOVEAN S C, BOERIU A M, AKABAH P S, et al. Optical biopsy strategy for the assessment of atrophic gastritis, intestinal metaplasia, and dysplasia[J]. Rom J Morphol Embryol, 2018, 59(2): 505-512.
    [14]
    娄书伟, 仝亚旭. 替普瑞酮对萎缩性胃炎伴幽门螺杆菌感染患者的疗效及对胃黏膜的影响[J]. 广东医学, 2019, 40(3): 450-454. https://www.cnki.com.cn/Article/CJFDTOTAL-GAYX201903033.htm

    LOU S W, TONG Y X. Therapeutic effect of teprenone on atrophic gastritis with Helicobacter pylori infection and its effect on gastricmucosa[J]. Guangdong Medical Journal, 2019, 40(3): 450-454. https://www.cnki.com.cn/Article/CJFDTOTAL-GAYX201903033.htm
    [15]
    时小红, 周利民. 慢性萎缩性胃炎诊疗思想认识及基础研究[J]. 中华全科医学, 2019, 17(10): 1687-1690, 1707. doi: 10.16766/j.cnki.issn.1674-4152.001030

    SHI X H, ZHOU L M. The theories and fundamental research on chronic atrophic gastritis[J]. Chinese Journal of General Practice, 2019, 17(10): 1687-1690, 1707. doi: 10.16766/j.cnki.issn.1674-4152.001030
    [16]
    陈维平. 奥美拉唑联合替普瑞酮治疗慢性浅表性胃炎的临床疗效[J]. 临床合理用药杂志, 2020, 13(30): 102-103. https://www.cnki.com.cn/Article/CJFDTOTAL-PLHY202030045.htm

    CHEN W P. Clinical efficacy of omeprazole combined with teprenone in the treatment of chronic superficial gastritis[J]. Chinese Journal of Clinical Rational Drug Use, 2020, 13(30): 102-103. https://www.cnki.com.cn/Article/CJFDTOTAL-PLHY202030045.htm
    [17]
    刘慧, 郁磊, 张诒凤, 等. 替普瑞酮改良四联疗法治疗幽门螺旋杆菌阳性胃溃疡患者效果及对胃黏膜形态、TGF-β、Smad 3、胃肠激素影响[J]. 临床误诊误治, 2020, 33(5): 38-43. https://www.cnki.com.cn/Article/CJFDTOTAL-LCWZ202005010.htm

    LIU H, YU L, ZHANG Y F, et al. Clinical Effect of Modified Teprenone-containing Quadruple Therapy in the Treatment of Patients with Helicobacter Pylori Positive Gastric Ulcer and Its Effect on the Morphology of Gastric Mucosa, Expression of TGF-β, Smad 3 and Gastrointestinal Hormones[J]. Clinical Misdiagnosis & Mistherapy, 2020, 33(5): 38-43. https://www.cnki.com.cn/Article/CJFDTOTAL-LCWZ202005010.htm
    [18]
    梁功臣, 刘国青. 奥美拉唑联合替普瑞酮治疗慢性浅表性胃炎的临床观察[J]. 临床合理用药杂志, 2021, 14(26): 97-99. https://www.cnki.com.cn/Article/CJFDTOTAL-PLHY202126037.htm

    LIANG G C, LIU G Q. Clinical observation of omeprazole combined with teprenone in the treatment of chronic superficial gastritis[J]. Chinese Journal of Clinical Rational Drug Use, 2021, 14(26): 97-99. https://www.cnki.com.cn/Article/CJFDTOTAL-PLHY202126037.htm
    [19]
    SUGANO K. Vonoprazan fumarate, a novel potassium-competitive acid blocker, in the management of gastroesophageal reflux disease: safety and clinical evidence to date[J]. Therap Adv Gastroenterol, 2018, 11: 1756283X17745776. DOI: 10.1177/1756283X17745776.
    [20]
    MARABOTTO E, ZIOLA S, SAVARINO V, et al. Vonoprazan fumarate for the treatment of gastric ulcers: a short review on emerging data[J]. Clin Exp Gastroenterol, 2020, 13: 99-104.
    [21]
    ZHANG M R, PANG M G, ZHANG M. Efficacy and safety of potassium-competitive acid blockers versus proton pump inhibitors as Helicobacter pylori eradication therapy: a meta-analysis of randomized clinical trials[J]. Clinics(Sao Paulo), 2022, 77: 100058. DOI: 10.1016/j.clinsp.2022.100058.
    [22]
    XIAO Y L, ZHANG S T, DAI N, et al. Phase Ⅲ, randomised, double-blind, multicentre study to evaluate the efficacy and safety of vonoprazan compared with lansoprazole in Asian patients with erosive oesophagitis[J]. Gut, 2020, 69(2): 224-230.
    [23]
    KOMORI H, UEYAMA H, NAGAHARA A, et al. A prospective ran domized trial of a potassium competitive acid blocker vs protonpump inhibitors on the effect of ulcer healing after endoscopic submucosal dissection of gastric neoplasia[J]. J Int Med Res, 2019, 47(4): 1441-1452.
    [24]
    孟丽英. 萎缩性胃炎患者血清胃泌素-17及胃蛋白酶原水平检测及临床意义[J]. 山西医药杂志, 2018, 47(22): 2694-2696. https://www.cnki.com.cn/Article/CJFDTOTAL-SXYY201822025.htm

    MENG L Y. Detection and clinical significance of serum gastrin-17 and pepsinogen levels in patients with atrophic gastritis[J]. Shanxi Medical Journal, 2018, 47(22): 2694-2696. https://www.cnki.com.cn/Article/CJFDTOTAL-SXYY201822025.htm
    [25]
    黄志远, 邹蕾, 杨桥, 等. 血清G-17、PG在合并2型糖尿病的Hp感染消化性溃疡和慢性萎缩性胃炎患者中的变化及意义[J]. 中国卫生工程学, 2022, 21(3): 520-521, 523. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGWX202203059.htm

    HUANG Z Y, ZOU L, YANG Q, et al. Changes and significance of serum G-17 and PG in patients with Hp infection peptic ulcer and chronic atrophic gastritis complicated with type 2 diabetes mellitus[J]. Chinese Journal of Public Health Engineering, 2022, 21(3): 520-521, 523. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGWX202203059.htm
    [26]
    GUNARATNE A W, HAMBLIN H, CLANCY A, et al. Combinations of antibiotics and vonoprazan for the treatment of Helicobacter pylori infections-exploratory study[J]. Helicobacter, 2021, 26(5): e12830. DOI: 10.1111/hel.12830.
    [27]
    路理杰, 杨阔, 刘华一. 情志因素与慢性萎缩性胃炎患者病理结果的相关性[J]. 中医杂志, 2021, 62(4): 324-327. https://www.cnki.com.cn/Article/CJFDTOTAL-ZZYZ202104013.htm

    LU L J, YANG K, LIU H Y. Correlation of emotional factors with pathological findings of chronic atrophic gastritis patients[J]. Journal of Traditional Chinese Medicine, 2021, 62(4): 324-327. https://www.cnki.com.cn/Article/CJFDTOTAL-ZZYZ202104013.htm
    [28]
    ZHAO X, ZHANG Z, LU F, et al. Effects of CYP2C19 genetic polymorphisms on the cure rates of H. pylori in patients treated with the proton pump inhibitors: an updated meta-analysis[J]. Front Pharmacol, 2022, 13: 938419. DOI: 10.3389/fphar.2022.938419.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(1)  / Tables(3)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (138) PDF downloads(9) Cited by()
    Proportional views
    Related

    Address：No. 287, Changhuai Road, Bengbu, Anhui Province, 233004, P.R.ChinaphoneNo：0552-3066635； 0552-3051890Email：zhqkyx@163.com

    Copyright © Chinese Journal of General Practice皖ICP备2020018345号-2

    Supported by: Beijing Renhe Information Technology Co., Ltd.    

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return